A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth-Hitchcock Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects who have been treated with AMG0001 in the AG-CLI-0206 study.
- Subjects who have provided consent for this long term follow-up study either directly or through a legally authorized representative.
- Subjects who have provided a release of information to the sponsor.
Exclusion Criteria:
- Subjects who were not enrolled in the AGCLI-0206 study.
- Subjects who enrolled in AG-CLI-0206 and who were not treated with AMG0001.
- Subjects who have not provided consent to this long term follow-up study either directly or through a legally authorized representative.
- Subjects who have not provided a release of information for the Sponsor to contact them directly via phone, email and/or mail.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Subjects who received AMG0001
Subjects from Study AG-CLI-0206 who received the study product AMG0001
|
Subjects from Study AG-CLI-0206 who received the study product AMG0001
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assess the long term safety of subjects from the AG-CLI-0206 study who have been treated with AMG0001
Time Frame: 3 years from the date last subject randomized into AG-CLI-0206 study
|
A health questionnaire will be used to collect specific information from the subject every 6 months
|
3 years from the date last subject randomized into AG-CLI-0206 study
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AG-CLI-0206-LTFU
- 2016-003491-41 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.